Dr Peter Hotez | Dean, National School of Tropical Medicine, Director, Texas Children’s Hospital Center
Baylor College of Medicine

Dr Peter Hotez, Dean, National School of Tropical Medicine, Director, Texas Children’s Hospital Center, Baylor College of Medicine

Peter J. Hotez, M.D., Ph.D. is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Director of the Texas Children’s Center for Vaccine Development (CVD) and Texas Children’s Hospital Endowed Chair of Tropical Pediatrics.  He is also University Professor at Baylor University, and Fellow in Disease and Poverty at the James A Baker III Institute for Public Policy.
Dr. Hotez is an internationally-recognized physician-scientist in neglected tropical diseases and vaccine development.  As head of the Texas Children’s CVD  he leads the only product development partnership for developing new vaccines for hookworm infection, schistosomiasis, and Chagas disease, and SARS/MERS, diseases affecting hundreds of millions of children and adults worldwide.  In 2006 at the Clinton Global Initiative he co-founded the Global Network for Neglected Tropical Diseases to provide access to essential medicines for hundreds of millions of people 
He obtained his undergraduate degree in molecular biophysics from Yale University in 1980 (phi beta kappa), followed by a Ph.D. degree in biochemistry from Rockefeller University in 1986, and an M.D. from Weil Cornell Medical College in 1987.  Dr. Hotez has authored more than 400 original papers and is the author of the acclaimed Forgotten People, Forgotten Diseases (ASM Press) and the recently released Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor amid Wealth (Johns Hopkins University Press). 
Dr. Hotez served previously as President of the American Society of Tropical Medicine and Hygiene and he is founding Editor-in-Chief of PLoS Neglected Tropical Diseases. He is an elected member of the National Academy of Medicine, and in 2011 he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the WHO.  In 2014-16 he served in the Obama Administration as US Envoy, focusing on vaccine diplomacy initiatives between the US Government and countries in the Middle East and North Africa.  
In 2015, Prof. Hotez emerged as a major national thought leader on the Zika epidemic in the Western Hemisphere and globally.  He was among the first to predict Zika’s emergence in the US and is called upon frequently to testify before US Congress, and served on infectious disease task forces for two consecutive Texas Governors.  For these efforts in 2017 he was named by FORTUNE Magazine as one of the 34 most influential people in health care.
In addition, as both a vaccine scientist and autism Dad he has led national efforts to defend vaccines and to serve as an ardent champion of vaccines going up against a growing national “antivaxx” threat.   He appears frequently on television (including BBC, CNN, Fox News, and MSNBC), radio, and in newspaper interviews (including the New York Times, USA Today, Washington Post, and Wall Street Journal).


West Coast Day 1 @ 08:00

Chair's Opening Remarks

West Coast Day 1 @ 08:30

Addressing the epidemic of misinformation

  • What are the key drivers of hesitancy to vaccinate?
    • Complacency, convenience and confidence
  • What works in tackling misinformation and building trust?
    • E.g. what steps are being taken to counteract sophisticated social media campaigns of parent groups?
  • What responsibility do public health and education authorities have and how can companies get involved?

West Coast Day 1 @ 14:00

Lunchtime presentation & book signing: “Vaccines did not cause Rachel’s Autism”

West Coast Day 1 @ 17:20

Panel: Is there a future for arbovirus vaccines?

  • What is the current landscape for dengue, zika and other arbovirus vaccines?
  • Which other arboviruses should be prioritized for vaccine development or for improvements of the existing vaccine(s)?
  • What might emerging arboviruses look like and what improvements are needed in current vaccines?
  • Finding a better way to evaluate these vaccines before going into phase 3 trials.
  • Using human protection models to discover the keys to eliciting a protective immune response
  • How will the immune response to one virus affect that of another?
  • What are the challenges to funding and commercializing arbovirus vaccines?
last published: 22/Nov/18 11:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156


To speak:
Lauren Sheppard
+44 (0)207 092 1211